Carson Wealth (CWM LLC)
PLX icon

Carson Wealth (CWM LLC)’s Protalix BioTherapeutics PLX Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33K Buy
1,534
+1,331
+656% +$3.3K ﹤0.01% 5155
2025
Q4 		$0 Buy
203
+40
+25% +$82 ﹤0.01% 5576
2025
Q3 		$0 Buy
+163
New +$265 ﹤0.01% 5474
2024
Q3 		– Sell
-845
Closed -$1K – 5071
2024
Q2 		$1K Buy
845
+839
+13,983% +$991 ﹤0.01% 4454
2024
Q1 		$0 Buy
+6
New +$9 ﹤0.01% 4649

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Carson Wealth (CWM LLC)'s PLX Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Protalix BioTherapeutics (PLX) stake by 656% in Q1 2026, buying an estimated $3.3K and bringing the position to 1,534 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #5155.

Carson Wealth (CWM LLC) first reported a position in PLX in Q1 2024 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Carson Wealth (CWM LLC) held 1,534 shares of Protalix BioTherapeutics worth $3.33K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 1,331 Protalix BioTherapeutics shares in Q1 2026, an estimated $3.3K.
  • Protalix BioTherapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #5155 holding.
  • Carson Wealth (CWM LLC) first reported a position in Protalix BioTherapeutics in Q1 2024 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.